Machine Learning–Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Machine Learning Model for Predicting Risk in Transthyretin Amyloid Cardiomyopathy

  • By

  • Giovanni Baj

  • Nicola Ciocca

  • Pooya Mohammadi Kazaj

  • Xuan Ma

  • Annina A. Studer Bruengger

  • Simon F. Stämpfli

  • Niklas F. Ehl

  • Sarah Hugelshofer

  • Otmar Pfister

  • Joëlle Lehmann

  • Christoph Ryffel

  • Lukas Hunziker

  • Michael Poledniczek

  • Andreas Kammerlander

  • George C. M. Siontis

  • Stephan Windecker

  • Moritz J. Hundertmark

  • Christian Nitsche

  • Isaac Shiri

  • Christoph Gräni

  • October 1, 2026

Share

Original Source(s)

Machine Learning–Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy

  • by Giovanni Baj, Nicola Ciocca, Pooya Mohammadi Kazaj, Xuan Ma, Annina A. Studer Bruengger, Simon F. Stämpfli, Niklas F. Ehl, Sarah Hugelshofer, Otmar Pfister, Joëlle Lehmann, Christoph Ryffel, Lukas Hunziker, Michael Poledniczek, Andreas Kammerlander, George C. M. Siontis, Stephan Windecker, Moritz J. Hundertmark, Christian Nitsche, Isaac Shiri, Christoph Gräni

  • October 1, 2026

Related Content

Notice of Retraction and Replacement. Ekwunife O et al. Social Risk Factors and Disparities in Advanced

Roxadustat Treatment After PCI Among Patients With ST-Segment Elevation Myocardial Infarction: A Randomized

Mortality score may refine heart allocation

A laboratory- and device-based model outperformed the current 6-status system in predicting short-term mortality among heart transplant candidates.